News

Cutaneous LE Linked To Increased Cancer Risk


 

GOTHENBURG, SWEDEN — Patients with cutaneous lupus erythematosus appear to have an elevated overall risk of cancer, especially nonmelanoma skin cancer, lung cancer, and non-Hodgkin's lymphoma.

That's the preliminary conclusion from a Swedish national cohort study involving 3,788 Swedes with cutaneous LE (CLE), each matched to three controls and followed for an average of 4.1 years, said Dr. Carina M. Grönhagen.

The take-home message from this first-ever look at the cancer risk associated with CLE is that patients with this skin disease need to be followed regularly for the emergence of malignancy. And they need a strong antismoking message.

“Many of these cancers are connected to smoking, and patients with CLE are known to be smokers to a higher degree than in a normal population,” observed Dr. Grönhagen, a dermatology resident at Danderyd Hospital and doctoral candidate in medical epidemiology at the Karolinska Institute, Stockholm.

She looked at cancer rates in patients with CLE because CLE is an autoimmune disease, and epidemiologic studies indicate other autoimmune diseases are associated with increased cancer risk.

The overall number of cases of cancer documented in the CLE group during the study period was 188, compared with an expected 112. This 67% increased incidence rate ratio remained significant after adjustment for comorbid SLE, which dropped the ratio only to 60%.

The greatest increase in cancer risk seen in the CLE cohort was for nonmelanoma skin cancer, with a 4.3-fold relative risk, compared with controls. The other strongest risk increases were the 2.9-fold increase in lung cancer, the 2.7-fold increase in non-Hodgkin's lymphoma, and the 2.7-fold rise in buccal cancer.

Asked if she thinks the observed increase in cancer in association with CLE is caused by the skin disease itself, or instead perhaps the immunosuppressive therapies employed in its treatment, Dr. Grönhagen replied that the well-established high rate of smoking among CLE patients is probably a significant contributor. But the immunologic derangement inherent in CLE is also likely to play a role, especially with regard to the increase in nonmelanoma skin cancer.

She declared having no relevant financial relationships.

Recommended Reading

Methotrexate May Benefit Juvenile Scleroderma
MDedge Rheumatology
Expert Outlines Drug-Development Obstacles in Lupus
MDedge Rheumatology
Catheter Is Best for Diagnosing Scleroderma PAH : Echocardiograms aren't accurate enough, can't distinguish causes of pulmonary artery pressure.
MDedge Rheumatology
Cyclophosphamide Is of Most Benefit for Worst SSc-ILD
MDedge Rheumatology
More Clinical Disorders Are Linked to APS
MDedge Rheumatology
Biologics Have Advanced Therapy in Systemic Vasculitis
MDedge Rheumatology
Tips for Predicting High-Risk Pregnancies in SLE
MDedge Rheumatology
Vitamin D Repletion in SLE Requires at Least 2,000 IU Daily
MDedge Rheumatology
Urinary Retention in SLE? Think Gray Matter Myelitis
MDedge Rheumatology
Belimumab May Be First Biologic Okayed for SLE
MDedge Rheumatology